Australian researchers have discovered that a bedtime nasal spray has the potential to reduce the severity of obstructive sleep apnoea (OSA) in people and lower their blood pressure. The findings offer hope to millions of people around the world affected by OSA, a common and debilitating chronic respiratory condition.
"Obstructive sleep apnoea (OSA) is a sleep disorder where the muscles in the back of the throat relax and the upper airway narrows or collapses, restricting oxygen intake and causing people to wake repeatedly throughout the night," says Professor Danny Eckert, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. "It has been linked to a variety of medical conditions including cardiovascular disease, stroke, obesity, diabetes, anxiety and depression. Treatment options are limited and while continuous positive airway pressure (CPAP) machines are a proven treatment for OSA, around 50% of people struggle to tolerate them," he says.
The aim of the study was to determine the effects of a new potassium channel blocker nasal spray on OSA severity and to investigate the potential influence of different breathing approaches such as restricted 'nasal only' breathing and the physiological characteristics of those who had a favourable response.
"Potassium channel blockers are a class of drugs that block the potassium channel in the central nervous system. When used in a nasal spray, the blockers have the potential to increase the activity of the muscles that keep the upper airway open and reduce the likelihood of the throat collapsing during sleep," added lead author, Dr Amal Osman, also from Flinders University.
Using a randomised, blind trial, ten people with OSA were given either the potassium blocker nasal spray, a placebo nasal spray or the potassium nasal spray in combination with restricted 'nasal only' breathing.
Seven out of the ten people responded to the potassium channel blocker nasal spray showing a reduction in the frequency of upper airway collapsing episodes during sleep and lower blood pressure the next morning. The use of the spray with restricted 'nasal only' breathing did not improve quality of sleep in this trial.
"What we have discovered is that the nasal spray application of the potassium channel blocker that we tested is safe, well tolerated. Those who had a physiological improvement in their airway function during sleep also had between 25–45% reductions in markers of their OSA severity including improved oxygen levels as well as a reduction in their blood pressure the next day," said Osman.
"These insights provide a potential pathway for development of new therapeutic solutions for those people with OSA who are unable to tolerate CPAP machines and/or upper airway surgery, and those with a desire for alternatives to existing therapies," concluded Eckert. "Right now, there are no approved drugs for treating OSA, but through these findings and future research we are getting closer to developing new and effective drugs that are safe and easy to use.”
Th findings were reported in the paper, ‘A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial,” published in the American Journal of Physiology-Heart and Circulatory Physiology. To access this paper, please click here